Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Phase II Randomized Trial of Stereotactic Radiotherapy (SRT) Followed by Intravitreal Aflibercept Injection for Patients With Ocular Melanoma
Sponsor: Regeneron Pharmaceuticals
Terminated
Slow accrual
Other terminated trials from Regeneron Pharmaceuticals
Other Uveal Melanoma trials with similar outcome
Listed as NCT03712904, this PHASE2 trial focuses on Uveal Melanoma and remains terminated or withdrawn. Sponsored by Regeneron Pharmaceuticals, it has been updated 14 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
-
Oct 2025 — Feb 2026 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Sep 2024 — Oct 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 9 earlier versions
-
Dec 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2019 — Jun 2019 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2019 — Apr 2019 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Regeneron Pharmaceuticals
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
For direct contact, visit the study record on ClinicalTrials.gov .